Olszewska Lidia, Merks Piotr, Religioni Urszula, Jakubek Ewa, Jarząbek-Bielecka Grażyna, Englert-Golon Monika, Kędzia Witold, Plagens-Rotman Katarzyna
University Clinical Hospital, Poznań, Poland.
Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warszawa, Poland.
Prz Menopauzalny. 2025 Jun;24(2):102-112. doi: 10.5114/pm.2025.152126. Epub 2025 Jun 16.
The use of vascular ports in oncology patients for the administration of irritating and chemotherapeutic drugs clearly solves the problem of peripheral vascular damage caused by oncological drugs, and at the same time provides a comfortable way of treating patients in the long term. Although there are risks associated with the long-term maintenance of implanted ports, any risk factors for infection associated with an implantable intravenous port should be minimized.
The main purpose of the study was to investigate the reasons for removal of vascular ports in patients undergoing systemic treatment at the wards of the University Clinical Hospital. Patients who had a vascular port implanted for the duration of their therapy were monitored for complications that had become the reason for removing the implants within 24 months of implantation.
The main reason for removing a vascular port was the conclusion of therapy (82.7%). The second reason for removing the ports was infection (13.5%), which, despite the use of rigorous procedures, could not be avoided due to the significant reduction in immunity in patients treated with oncological drugs.
Despite their limitations in oncological treatment, ports have no alternatives, and thus further technological progress is essential. Education of staff working with patients with implants allows an increase in the benefits of therapy in the long run and significantly improves the quality of life of oncological patients. The education of patients and their families, as well as frequent re-training of staff, provides greater opportunities to minimize the side effects of therapy and reduce the number of adverse reactions related to infections.
在肿瘤患者中使用血管通路端口来输注刺激性和化疗药物，显然解决了肿瘤药物导致的外周血管损伤问题，同时为患者提供了一种长期舒适的治疗方式。尽管长期维护植入式端口存在风险，但与植入式静脉端口相关的任何感染风险因素都应降至最低。
本研究的主要目的是调查大学临床医院病房接受全身治疗的患者移除血管通路端口的原因。对在治疗期间植入血管通路端口的患者进行监测，观察在植入后24个月内导致移除植入物的并发症。
移除血管通路端口的主要原因是治疗结束（82.7%）。移除端口的第二个原因是感染（13.5%），尽管采取了严格的程序，但由于接受肿瘤药物治疗的患者免疫力显著下降，感染仍无法避免。
尽管端口在肿瘤治疗中有其局限性，但没有其他替代方案，因此进一步的技术进步至关重要。对与植入患者打交道的工作人员进行培训，从长远来看可以增加治疗的益处，并显著提高肿瘤患者的生活质量。对患者及其家属进行教育，以及对工作人员进行频繁的再培训，为最大限度地减少治疗副作用和减少与感染相关的不良反应数量提供了更多机会。
